Letter.

Letter Published in The National UAe on 23Feb 14Pharma policy needs rethinking

The news article India clamps down on clinical drug trials, at a cost (February 20) was an interesting read.

India has introduced restrictions on clinical trials following concerns about the safety of test patients, and it has become a much more complex and lengthy process to secure permission for trials. As a result, many companies were compelled to shift their trial bases abroad.

India has the largest number of pharmaceutical factories approved by the FDA outside of the US. That’s why India needs to rethink its policies over clinical trials.

The country has seen dramatic developments over the years in the pharmaceutical export market. That is all the more reason for it to eliminate this issue as soon as possible.

K Ragavan, India